| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| venetoclax multiple myeloma | 1.8 | 1 | 9867 | 21 | 27 |
| venetoclax | 0.97 | 0.6 | 6698 | 96 | 10 |
| multiple | 1.08 | 0.7 | 5168 | 92 | 8 |
| myeloma | 1.06 | 0.1 | 2651 | 67 | 7 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| venetoclax multiple myeloma | 0.42 | 0.5 | 9852 | 94 |
| venetoclax multiple myeloma dosing | 1.42 | 0.1 | 3094 | 45 |
| venetoclax multiple myeloma approval | 0.46 | 0.8 | 3134 | 77 |
| venetoclax multiple myeloma clinical trials | 0.84 | 0.2 | 9202 | 56 |
| venetoclax multiple myeloma t 11 14 | 1.94 | 0.6 | 7727 | 75 |
| venetoclax multiple myeloma fda | 1.47 | 0.8 | 8200 | 79 |
| venetoclax multiple myeloma filing | 0.55 | 0.4 | 8606 | 69 |
| venetoclax multiple myeloma refractory | 0.77 | 0.2 | 1085 | 97 |
| venetoclax approved for multiple myeloma | 0.12 | 0.5 | 3166 | 94 |
| venetoclax daratumumab multiple myeloma | 0.57 | 0.2 | 4643 | 65 |
| venetoclax and bortezomib multiple myeloma | 0.43 | 0.4 | 2134 | 24 |
| abbvie venetoclax multiple myeloma | 1.56 | 0.1 | 1814 | 99 |
